CATX FY2025 EPS Estimate Reduced by Cantor Fitzgerald

Perspective Therapeutics, Inc. (NYSE:CATX) – Equities research analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for Perspective Therapeutics in a research report issued to clients and investors on Thursday, August 14th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($1.05) per share for the year, down from their previous forecast of ($1.04). The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Cantor Fitzgerald also issued estimates for Perspective Therapeutics’ FY2026 earnings at ($0.94) EPS.

Several other research firms also recently issued reports on CATX. B. Riley restated a “buy” rating and set a $12.00 price objective (up previously from $9.00) on shares of Perspective Therapeutics in a report on Monday, June 23rd. Truist Financial cut their price objective on Perspective Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. Royal Bank Of Canada upgraded Perspective Therapeutics from an “outperform” rating to a “moderate buy” rating and boosted their price objective for the stock from $15.00 to $16.00 in a report on Tuesday, June 3rd. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Saturday, July 12th. Finally, Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Monday, June 23rd. One analyst has rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $12.56.

Perspective Therapeutics Price Performance

Shares of NYSE CATX opened at $3.61 on Monday. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $16.55. The firm has a 50-day moving average of $3.76 and a two-hundred day moving average of $2.95.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of Perspective Therapeutics in the fourth quarter valued at $4,132,000. Two Sigma Advisers LP acquired a new position in shares of Perspective Therapeutics in the fourth quarter valued at $484,000. JPMorgan Chase & Co. raised its stake in shares of Perspective Therapeutics by 498.3% in the fourth quarter. JPMorgan Chase & Co. now owns 149,045 shares of the company’s stock valued at $475,000 after purchasing an additional 124,133 shares in the last quarter. Two Sigma Investments LP acquired a new position in Perspective Therapeutics during the fourth quarter worth $2,075,000. Finally, Jump Financial LLC acquired a new position in Perspective Therapeutics during the fourth quarter worth $688,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.